-
Je něco špatně v tomto záznamu ?
Ivabradine, coronary heart disease, and heart failure: time for reappraisal
T. Stulc, R. Ceška,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu komentáře, časopisecké články
- MeSH
- benzazepiny terapeutické užití MeSH
- lidé MeSH
- nemoci koronárních tepen farmakoterapie MeSH
- srdeční frekvence účinky léků MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
Ivabradine is generally considered to be a safe drug with well-established and substantial benefits. Nevertheless, recently published results from the SIGNIFY trial suggest that ivabradine has rather inconsistent effects on cardiovascular outcomes. In addition, careful examination of all available data from ivabradine trials reveals signals of harm that have not yet been appropriately addressed, including a markedly increased incidence of atrial fibrillation and increased risk of cardiovascular events in patients with heart rates below 70 bpm. These concerns warrant consideration, since they could have implications for the future use of ivabradine.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022968
- 003
- CZ-PrNML
- 005
- 20150729105929.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11883-014-0463-8 $2 doi
- 035 __
- $a (PubMed)25301354
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Stulc, Tomáš $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, 128 21, Prague, Czech Republic, TSTULC@LF1.CUNI.CZ.
- 245 10
- $a Ivabradine, coronary heart disease, and heart failure: time for reappraisal / $c T. Stulc, R. Ceška,
- 520 9_
- $a Ivabradine is generally considered to be a safe drug with well-established and substantial benefits. Nevertheless, recently published results from the SIGNIFY trial suggest that ivabradine has rather inconsistent effects on cardiovascular outcomes. In addition, careful examination of all available data from ivabradine trials reveals signals of harm that have not yet been appropriately addressed, including a markedly increased incidence of atrial fibrillation and increased risk of cardiovascular events in patients with heart rates below 70 bpm. These concerns warrant consideration, since they could have implications for the future use of ivabradine.
- 650 _2
- $a benzazepiny $x terapeutické užití $7 D001552
- 650 _2
- $a nemoci koronárních tepen $x farmakoterapie $7 D003324
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 655 _2
- $a komentáře $7 D016420
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ceška, Richard
- 773 0_
- $w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 16, č. 12 (2014), s. 463
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25301354 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150729110015 $b ABA008
- 999 __
- $a ok $b bmc $g 1083307 $s 905961
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 16 $c 12 $d 463 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
- LZP __
- $a Pubmed-20150709
